Abstract:Key PointsThe phosphatidylinositol-3-kinase (PI3K) pathway plays a crucial role in cell growth and survival and is activated in various cancers. Multiple components of the pathway are frequently targeted by amplification, mutation, and, less commonly, translocation in neoplasia; there is also crosstalk with the p53 and retinoblastoma pathways to comprise a signalling network that promotes tumour initiation and progression.Despite major interest in this pathway for cancer drug discovery, no drugs have yet been approved that act specifically against PI3K or its downstream regulator, AKT. However, several drugs that were developed for other purposes either directly or indirectly target PI3K signaling, such as the rapamycin analogs, the ether lipids perifosine and miltefosine, and inhibitors of the epidermal growth factor receptor (EGFR), HER2, c-kit, platelet-derived growth factor receptor (PDGFR) and bcr–abl.Because of the crucial role of the PI3K pathway in normal cell growth and in the cellular response to stress, the main challenge to developing PI3K pathway-targeted drugs is to identify inhibitors with a usable therapeutic index.It is likely that PI3K inhibitors will need to be used in combination with other drugs that induce cell stress, such as other signaling inhibitors, radio- and chemotherapy.Points at which therapeutic intervention might be useful in the PI3K pathway include PI3K itself, the downstream regulator AKT, although toxicity has thus far precluded use of specific inhibitors of this crucial signaling node, and other downstream components such as mTOR, integrin-linked kinase (ILK), phosphoinositide-dependent kinase-1 (PDK-1), p70S6 kinase, and Forkhead/FOXO1.As with other molecularly targeted agents such as imatinib mesylate (Gleevec) and trastuzumab (Herceptin), the success of PI3K inhibitors will probably depend on the selection of cancer patients likely to be responders based on genomic aberrations. The co-development of molecular markers determining early response will allow triage of non-responders to other therapies and thereby increase the utility of targeted agents.

Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer.

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

TGF-&beta; Signaling in Cancer Metastasis

Targeting PI3K/Akt signal transduction for cancer therapy

Targeting TGF-β Signaling in Cancer.

Role of PI3K/Akt Signaling Pathway in Tumor Progress and Treatment

Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Roles of TGF-β Signaling Pathway in Tumor Microenvirionment and Cancer Therapy.

Biphasic Role of TGF-β in Cancer Progression: From Tumor Suppressor to Tumor Promotor

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

TGF-β signaling: critical nexus of fibrogenesis and cancer

Transforming growth factor-beta signaling and tumor angiogenesis.

PI3K: a potential therapeutic target for cancer.

Transforming Growth Factor Β Signaling Pathway: A Promising Therapeutic Target for Cancer

Targeting the transforming growth factor-β signaling pathway in human cancer

Targeting TGFβ signal transduction for cancer therapy

The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions

The PTEN–PI3K Axis in Cancer

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Transforming Growth Factor Beta Signaling Pathway: A Promising Therapeutic Target For Cancer